Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Nobuki, Furubayashi"'
Autor:
Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Kenichi Harada, Motonobu Nakamura, Naohiro Fujimoto
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 862-871 (2024)
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. He
Externí odkaz:
https://doaj.org/article/090e7c2b79cf474b85e1f11873b1d392
Autor:
Kaede Morihara, Takahito Negishi, Nobuki Furubayashi, Hiroki Kobayashi, Mikako Jinnouchi, Kenji Shinozaki, Yutaka Koga, Kenichi Taguchi, Motonobu Nakamura
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 1460-1465 (2023)
Introduction: Dedifferentiated liposarcoma (DDLP) was initially defined as a tumor containing differentiated liposarcoma and distinct regions of nonlipogenic spindle cell or pleomorphic sarcoma. Retroperitoneal liposarcomas feature a characteristic a
Externí odkaz:
https://doaj.org/article/2b09ea72b60f4ecc802ccf7eabc6ce6d
Autor:
Shinkichi Takamori, Nobuki Furubayashi, Kenichi Taguchi, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Masafumi Yamaguchi, Ryo Toyozawa, Takashi Seto, Takahito Negishi, Motonobu Nakamura, Tatsuro Okamoto
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2122-2125 (2021)
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of non‐small cell lung cancer (NSCLC). With the increasing use of ICIs, clinicians should be familiar with their immune‐related adverse events, includ
Externí odkaz:
https://doaj.org/article/2a2caac2e4584c3fb28387f6506f550b
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0278039 (2022)
To determine the course of treatment while considering the patients' desires, we examined trends regarding patients' perception and expectations over the course of cancer pharmacotherapy. We retrospectively reviewed interview sheets filled in by pati
Externí odkaz:
https://doaj.org/article/011ba8d0a95b4af487fa56b119ad47f4
Autor:
Nobuki Furubayashi, Takahito Negishi, Hidenori Iwai, Kei Nagase, Kenichi Taguchi, Mototsugu Shimokawa, Motonobu Nakamura
Publikováno v:
Indian Journal of Urology, Vol 33, Iss 1, Pp 64-69 (2017)
Introduction: We aimed to determine whether the number and type of risk factors are associated with biochemical recurrence-free survival after radical prostatectomy in men with D'Amico intermediate-risk prostate cancer. Materials and Methods: Between
Externí odkaz:
https://doaj.org/article/0301e35b70b04a4dbd94b94cbd9f1a97
Autor:
Takahito Negishi, Tohru Nakagawa, Naotaka Nishiyama, Hiroshi Kitamura, Eijiro Okajima, Nobuki Furubayashi, Yoshifumi Hori, Kentarou Kuroiwa, Yuhyon Son, Narihito Seki, Toshihisa Tomoda, Motonobu Nakamura
Publikováno v:
Japanese Journal of Clinical Oncology. 52:1430-1435
Introduction Metastases from renal cell carcinoma develop in various organs. However, the breadth of discrepancy in response to immune checkpoint inhibitors across tumor sites within the same individual remains unclear. Patients and methods We review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b9f11fb4a7ab9c938472a0090f084a
https://doi.org/10.1093/jjco/hyac144
https://doi.org/10.1093/jjco/hyac144
Autor:
Nobuki, Furubayashi, Futoshi, Morokuma, Toshihisa, Tomoda, Yoshifumi, Hori, Takahito, Negishi, Akihiro, Miura, Hiroki, Komori, Kentaro, Kuroiwa, Motonobu, Nakamura
Publikováno v:
Anticancer Research. 42:1571-1577
The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear.Thirty-four patients who received pembrolizumab as second-line treatment after first-line platinum-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b507b1f1908827c6a1bf43e3163ef1
https://doi.org/10.21873/anticanres.15631
https://doi.org/10.21873/anticanres.15631
Autor:
Takahito Negishi, Akira Matsunobu, Makoto Endo, Ryouhei Yokoyama, Shuhei Kusano, Nobuki Furubayashi, Kenichi Taguchi, Yoshiyuki Shioyama, Keiichiro Iida, Toshifumi Fujiwara, Nokitaka Setsu, Yoshihiro Matsumoto, Yasuharu Nakashima, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Motonobu Nakamura
Publikováno v:
Oncology. 100:148-154
Introduction: Radiation-associated sarcoma (RAS) is one of the most life-threatening complications associated with the treatment of malignant neoplasms. Because all RAS patients have a history of radiotherapy, there have been no effective treatment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a011c0d7521593a5a34eaa0b117a4c
https://doi.org/10.1159/000521504
https://doi.org/10.1159/000521504
Autor:
Motonobu Nakamura, Naotaka Sakamoto, Narihito Seki, Nobuki Furubayashi, Toshihisa Tomoda, YooHyun Song, Yoshifumi Hori, Kentaro Kuroiwa, Shingo Tamura, Akinori Minato, Takahito Negishi, Naohiro Fujimoto
Publikováno v:
Cancer Management and Research
Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Shingo Tamura,7 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonobu Nakamura1 1Department of Urology, National Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500ce6b05fc6f03552cda80e7da5c04a
https://doi.org/10.2147/cmar.s333823
https://doi.org/10.2147/cmar.s333823
Autor:
TAKAHITO NEGISHI1 negishi-takahito@umin.ac.jp, NOBUKI FURUBAYASHI1, DAI TAKAMATSU1, KOUSUKE IEIRI1, NAOTAKA NISHIYAMA2, HIROSHI KITAMURA2, MOTONOBU NAKAMURA1
Publikováno v:
Oncology Letters. Nov2020, Vol. 20 Issue 5, p1-6. 6p.